Overview

A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.

Status:
Completed

Trial end date:
2017-10-01

Target enrollment:

Participant gender:

Summary

This is a study of how one or more injections of HSP-130 under the skin effect the white blood cell counts and drug levels in women with breast cancer that has not spread to distant sites in the body (non-metastatic). This will be studied in women before breast surgery or while receiving chemotherapy. Safety will also be studied. Additionally, the purpose of this study is to evaluate the effects and safety of single and multiple doses of HSP-130 in subjects with non-metastatic breast cancer. This study will determine the dose to move forward for future clinical trials.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Collaborators:

Hospira, Inc.
Hospira, now a wholly owned subsidiary of Pfizer

Treatments:

Lenograstim